L3MBTL histone methyl-lysine binding protein 2Genealiases: H-l(3)mbt-l · L3MBT
Q-omics provides the consensus-scored L3MBTL2 profile across patient tissues and cancer cell-line models. L3MBTL2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, L3MBTL2 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, L3MBTL2 protein abundance shows 24,787 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SCLC, LIHC, and LSCC as cancer lineages where L3MBTL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for L3MBTL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes L3MBTL2 survival associations across molecular data types. L3MBTL2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible L3MBTL2 RNA expression–survival associations across cancer types. High L3MBTL2 expression shows unfavorable associations in ACC and LIHC, but favorable associations in SCLC, KIRC, UCEC and READ. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for L3MBTL2 RNA expression.
This table summarizes L3MBTL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for L3MBTL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. L3MBTL2 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, KIRC, HNSC and COAD. The LIHC box plot shows higher L3MBTL2 RNA expression in tumor versus normal tissue (log2 FC = +1.212, t-test p < 0.001).
This table shows molecular features associated with L3MBTL2 in patient tissues and cancer cell lines. In patient samples, L3MBTL2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, L3MBTL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
